Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial
Viviana Galimberti(European Institute of Oncology), Bernard F. Cole(University of Vermont), Stefano Zurrida(European Institute of Oncology), Giuseppe Viale(University of Milan), Alberto Luini(European Institute of Oncology), Paolo Veronesi(University of Milan), Paola Baratella(European Institute of Oncology), Camelia Chifu(European Institute of Oncology), Manuela Sargenti(European Institute of Oncology), Mattia Intra(European Institute of Oncology), Oreste Gentilini(European Institute of Oncology), Mauro G. Mastropasqua(European Institute of Oncology), Giovanni Mazzarol(European Institute of Oncology), Samuele Massarut(Centro di Riferimento Oncologico), Jean‐Remi Garbay(Institut Gustave Roussy), Janez Žgajnar(Institute of Oncology Ljubljana), Hanne Galatius(Herlev Hospital), A. Recalcati(Alessandro Manzoni Hospital), David R. G. Littlejohn(Calvary Riverina Hospital), Monika Bamert(Breast Center), Marco Colleoni(European Institute of Oncology), Karen N. Price(Dana-Farber Cancer Institute), Meredith M. Regan(Harvard University), Aron Goldhirsch(European Institute of Oncology), Alan S. Coates(The University of Sydney), Richard D. Gelber(Harvard University), Umberto Veronesi(European Institute of Oncology)
Cited by 1,226Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis